SCHEDULE: FMR LLC Discloses 10% Stake in Relay Therapeutics

FMR LLC and Abigail P. Johnson have jointly filed a Schedule 13G, reporting beneficial ownership of 10.0% of Relay Therapeutics Inc.'s common stock as of July 31, 2026.

Summary

• FMR LLC, along with Abigail P. Johnson, has filed an amendment to their Schedule 13G, reporting their beneficial ownership of Relay Therapeutics Inc. common stock.
• As of July 31, 2026, the reporting persons collectively beneficially own 21,270,751.24 shares, representing 10.0% of the class of securities.
• FMR LLC holds sole voting power for 21,153,779.00 shares and sole dispositive power for 21,270,751.24 shares.
• Abigail P. Johnson has sole dispositive power for 21,270,751.24 shares.
• The filing indicates that other persons may have the right to receive or direct the sale of dividends from these shares, but no single other person holds more than 5%.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, indicating a significant institutional holding without immediate implications for control or strategy changes.

Positives

• Significant institutional ownership by FMR LLC and Abigail P. Johnson, indicating confidence in Relay Therapeutics.
• The reporting persons hold a substantial 10.0% stake, which can provide stability and potentially attract further investment.

Negatives

• The filing does not provide specific details on the investment strategy or rationale behind acquiring this stake.
• While FMR LLC has significant voting power, the filing notes that other persons may have rights to dividends or sale proceeds, suggesting a complex ownership structure.

Risks

• Potential for future changes in beneficial ownership by FMR LLC or Abigail P. Johnson, which could impact share price.
• The filing does not detail any specific risks related to Relay Therapeutics' business operations or financial health.

Future Outlook

The filing is primarily a disclosure of ownership and does not contain forward-looking statements or specific business outlooks for Relay Therapeutics.

Management Comments

• FMR LLC and Abigail P. Johnson certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Industry Context

StockSavvy.ai notes that significant institutional filings like this often signal sustained interest from major investment firms in the biotechnology sector, particularly in companies with novel therapeutic platforms.

Stakeholder Impact

• Shareholders: Increased institutional ownership may lead to greater stock liquidity and potentially more analyst coverage.
• Management: The filing confirms FMR LLC's passive investment approach, not seeking to influence control.

Next Steps

• FMR LLC and Abigail P. Johnson will continue to hold their beneficial ownership of Relay Therapeutics Inc. common stock.
• Future amendments to this Schedule 13G will be filed if there are material changes in beneficial ownership.

Key Dates

Keywords

Relay Therapeutics, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Investment Management